Ethical Dimensions of Drug Testing

Drug testing raises ethical issues in human safety, animal welfare, & scientific integrity, prompting India’s adoption of human-relevant methods & Biopharma SHAKTI to promote responsible innovation.

Current Status and Framework of Drug Testing in India

Regulatory Oversight: Central Drugs Standard Control Organisation (CDSCO) & Drugs Controller General of India (DCGI) supervise drug approvals & clinical trials to ensure safety & ethical compliance.
Legal Framework: Drugs & Cosmetics Act and New Drugs and Clinical Trials (NDCT) Rules guide preclinical, clinical, and post-marketing drug testing.
Clinical Trials: Phase I–IV trials with ethics committee approval and Clinical Trials Registry – India (CTRI) registration protect participants and ensure transparency.
Ethical Safeguards: Animal Ethics Committees, pharmacovigilance, and principles like non-maleficence and autonomy protect humans and animals.

Importance of Drug Testing

Safety Verification: Ensures that drugs do not cause harm to users, as seen in the Northwick Park trial where six volunteers suffered organ failure during a Phase I clinical study.
Effectiveness Check: Confirms that medicines produce the desired therapeutic results. E.g., semorinemab failed in Alzheimer’s patients despite preclinical success in mice.
Quality Assurance: Maintains high standards in drug production and administration. E.g., CDSCO oversees over 50,000 drugs in India to ensure safety and compliance.
Public Trust: Builds confidence in healthcare systems and pharmaceutical products, exemplified by the adoption of Biopharma SHAKTI to promote safe and affordable biologics.

Ethical Issues in Drug Testing

Human Safety: Protecting volunteers from harm upholds non-maleficence, as seen in the Northwick Park trial where six volunteers were harmed.
Scientific Integrity: Ensuring honesty and reproducibility demonstrates integrity and accountability, exemplified by semorinemab failing human trials despite animal success.
Animal Welfare: Minimizing animal suffering reflects compassion and adherence to the 3Rs (Replace, Reduce, Refine) principle, given India’s annual use of 3–4 lakh animals.
Informed Consent: Respecting autonomy and dignity ensure voluntary understanding and informed consent, highlighted when vulnerable participants join trials under financial pressure.
Justice Equity: Ensuring fair access to drugs embodies distributive justice and fairness, illustrated by expensive trastuzumab and delayed biosimilars.

Emerging Alternative Testing Methods

Organoids: Three-dimensional structures grown from human or stem cells that mimic specific organs, enabling accurate study of drug effects in a human context.
Organs-on-Chip: Microdevices lined with human cells that replicate blood flow, tissue interactions, and chemical signaling for precise drug testing.
3D Bioprinting: Technology that creates complex human tissues or organs using patient-specific cells, allowing personalized and biologically relevant drug testing.
Ethical Implications:
- Human Safety: Reduces risks to volunteers by providing predictive human-relevant models, upholding non-maleficence and the precautionary principle.
- Animal Welfare: Minimizes animal suffering in preclinical studies, reflecting compassion, the 3Rs principle, and virtue ethics.
- Scientific Integrity: Enhances reliability, reproducibility, and personalized relevance of drug research, promoting beneficence, justice, and professional responsibility.

Government Initiatives for Drug Testing in India

Biopharma SHAKTI: Launched in 2026 to boost domestic production of biologics and biosimilars with ₹10,000 crore funding.
NDCT Amendment 2023: Promotes non-animal methodologies (NAMs) and human-relevant models for safer and predictive drug testing.
CDSCO Oversight: Central regulatory body ensuring safety, efficacy, and ethical standards in clinical trials and biosimilar approvals.
Biosimilar Promotion: Policies prevent patent evergreening and facilitate affordable, equitable access to life-saving biologics.

Biologics are medicines made from living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.
Biosimilars are nearly identical, approved versions of original biologic drugs, offering similar safety, efficacy, and quality at lower costs.
Patent evergreening is the practice of extending a drug’s patent protection by making minor changes, delaying generic or biosimilar competition.

Challenges and Implementation Barriers

Limited Adoption: Despite over 90 academic labs working on NAMs, industry uptake remains low, slowing translation into practical drug testing.
Funding and Infrastructure: Even with ₹10,000 crore under Biopharma SHAKTI, sustained investment and scalable infrastructure are needed to operationalize human-relevant models.
Regulatory Delays: Draft guidelines for biosimilars and NAMs are not fully implemented, limiting confidence and adoption in the drug development ecosystem.
Market and Patent Barriers: Patent evergreening, high biologics costs, and low investor awareness hinder affordable biosimilars and equitable access to life-saving drugs.

Way Forward

Ethical Regulation: Strengthen guidelines and oversight (CDSCO) to integrate NAMs, upholding principle of non-maleficence and accountability.
Responsible Innovation: Promote human-relevant models and industry-academia collaboration, reflecting utilitarian ethics by maximizing human benefit.
Informed Consent: Ensure transparent risk communication and safeguards for vulnerable participants, respecting autonomy and Kantian dignity.
Access Equity: Prevent patent evergreening and promote affordable biosimilars, ensuring distributive justice and fairness.
Scientific Culture: Train researchers in bioethics and foster accountability and transparency, emphasizing virtue ethics and professional responsibility.

“Balancing innovation with ethics, India’s drug testing framework protects humans, animals, and public trust.” As Albert Einstein said, “Concern for man himself and his fate must always form the chief interest of all technical endeavors.”

Reference: The Hindu

PMF IAS Pathfinder for Mains – Question 604

Q. Critically examine whether the existing regulatory architecture in India is adequate to deal with ethical concerns arising from drug testing on humans and animals. What institutional reforms are required to ensure that scientific progress remains aligned with ethical responsibility? (250 Words) (15 Marks)

Approach

Introduction: Write a brief introduction about India’s drug testing system.
Body: Examine whether the existing regulatory architecture in India is adequate to deal with ethical concerns arising from drug testing on humans and animals, mention key challenges, and suggest institutional reforms.
Conclusion: Emphasis on Ethics-driven scientific innovation to ensure ethical drug testing in India.